

European Patent Office Declares Medinol Patent Invalid

(April 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the European Patent Office has declared invalid a patent held by Medinol Ltd. This is the patent that Boston Scientific's Express™ and TAXUS™ stent systems were found to infringe in The Netherlands. As a result, the injunction against the sale of these products in The Netherlands is no longer effective and Boston Scientific expects to recommence sales there immediately. The European Patent Office's decision is final and not appealable. Boston Scientific is considering whether to seek damages against Medinol in The Netherlands.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with commercialization of new technologies, third party intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.

<https://news.bostonscientific.com/medinol-patent-invalid>